<unk>  is orally available and prevents intracellular vesicle transport along microtubules, a part of the cytoskeleton. It binds to the colchicine binding site of the alpha and beta tubulin subunits of microtubules and crosslinks the microtubules, thereby inhibiting the polymerization of microtubules in tumor cells and tumor blood vessel endothelial cells. This blocks the formation of the mitotic spindle apparatus and leads to cell cycle arrest in the G2/M phase. As a result, this drug disrupts the tumor vasculature and blood flow in the tumor, depriving the tumor cells of nutrients and triggering apoptosis. In addition, since microtubules play an important role in intracellular transport, inhibition of their polymerization can interfere with the transport of the androgen receptor (AR) into the cell nucleus as well as the transport of a virus inside the cell. This can decrease viral replication and assembly of the virus. Inhibition of tubulin polymerization can also inhibit the release of pro-inflammatory cytokines and disrupt the activities of inflammatory cells.<unk>  is not a substrate of P-glycoprotein (Pgp), an efflux pump that, when overexpressed, can confer resistance to taxanes. In a phase III study on the treatment of severe courses of COVID-19,<unk>  reduced mortality by 55% according to the manufacturer. Because of the high efficacy, the test phase was stopped prematurely so that the drug no longer had to be withheld from the placebo control group.
Sabizabulin
Ciltacabtagene autoleucel
Brexucabtagene autoleucel
Nalmefene
Alcaftadine
Astemizole
Tebentafusp
Tecovirimat